PCNL in neurogenic bladder: A challenging population for both clinical management and analysis

Bridget Heijkoop; Bodie Chislett; Marlon Perera; Stephen Esler; Damien Bolton; David Rowan Webb

doi:10.1002/bco2.268

PCNL in neurogenic bladder: A challenging population for both clinical management and analysis

BJUI Compass. 2023 Jun 30;4(6):695-700. doi: 10.1002/bco2.268. eCollection 2023 Nov.

Authors

Bridget Heijkoop¹, Bodie Chislett¹, Marlon Perera¹, Stephen Esler¹, Damien Bolton^{1

2

3}, David Rowan Webb¹

Affiliations

¹ Austin Hospital Heidelberg Victoria Australia.
² Department of Urology Austin Health Heidelberg Victoria Australia.
³ Department of Surgery University of Melbourne Melbourne Victoria Australia.

Abstract

Objectives: To review the management of patients with neurogenic bladder undergoing percutaneous nephrolithotomy (PCNL) at our institution with the aim of assessing peri-operative morbidity.

Subjects/patients and methods: We conducted a retrospective review of all neurogenic bladder patients who underwent PCNL at our hospital in the last decade with the aim of assessing peri-operative morbidity.

Results: A total of 298 PCNL were performed during the study period of which 58 were in patients with a neurogenic bladder or urinary diversion, 33 of which were in SCI patients. Preoperative demographic and stone characteristics, intraoperative data and postoperative length of stay and complications are summarised in table form.

Conclusion: PCNL remains an acceptably safe and efficacious treatment for upper tract stone disease in patients with neurogenic bladders and will continue to have a valuable role where SCI prevents alternative approaches such as ureteroscopy.

Keywords: PCNL; neurogenic bladder; percutaneous nephrolithotomy; renal stones; spinal cord injury.